CLAVE and BHV Partners invest in MATCH biosystems, a biotechnology company that develops rapid pathogen detection tests in hospital and veterinary clinical settings.
The objective of MATCH biosystems is the development of a manageable, low-cost, non-invasive test, capable of accurately detecting the pathogen identified as a clinical target in a few minutes. With current devices, it takes between 24 and 72 hours, with the consequent delay in the final diagnosis and the increase in hospital costs. Therefore, the proposition of MATCH biosystems has a clinical validation that presents competitive advantages over current solutions.
see article in: